Filing Flows › Comparisons › INSP vs NVCR
Inspire Medical Systems vs NovoCure: INSP and NVCR compared
Inspire Medical Systems is the larger company: $207M of revenue in its latest quarter (Q3 2026) against $193M for NovoCure (Q3 2026). NovoCure is growing faster (+16% against -8% a year earlier). NovoCure is more profitable, with an operating margin of -3.2% against -13.9%.
Where the money goes: INSP and NVCR
Inspire Medical Systems (INSP) · Q3 2026
Inspire Medical Systems, Q3 2026: revenue $207M (-8% year over year), operating margin -13.9%, net loss $24.4M, operating cash flow $46.4M. The chart follows the revenue to costs, profit and cash.
NovoCure (NVCR) · Q3 2026
NovoCure, Q3 2026: revenue $193M (+16% year over year), operating margin -3.2%, net loss $10.4M, operating cash flow $22.7M. The chart follows the revenue to costs, profit and cash.
| Inspire Medical Systems (INSP) | NovoCure (NVCR) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $207M | $193M |
| Revenue growth, Y/Y | -8% | +16% |
| Operating margin | -13.9% | -3.2% |
| Net earnings | −$24.4M | −$10.4M |
| Net margin | -11.8% | -5.4% |
| Operating cash flow | $46.4M | $22.7M |
| Free cash flow | $38.9M | $15.7M |
| Market value | $2.0B | — |
| P/E | 20.6× | — |
| Analysts’ mean target | $69.62 | — |
Questions
Which is bigger, Inspire Medical Systems or NovoCure?
Inspire Medical Systems is the larger company: $207M of revenue in its latest quarter (Q3 2026) against $193M for NovoCure (Q3 2026).
Is Inspire Medical Systems or NovoCure growing faster?
NovoCure is growing faster (+16% against -8% a year earlier).
Which is more profitable, Inspire Medical Systems or NovoCure?
NovoCure is more profitable, with an operating margin of -3.2% against -13.9%.
More: Inspire Medical Systems earnings · how Inspire Medical Systems makes money · NovoCure earnings · how NovoCure makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 2, 2026; 10-Q filed Oct 29, 2026). Fiscal quarters can end on different dates. Not investment advice.